Innovative approaches to the preservation of the peritoneal membrane: From bench to bedside

Advances in Renal Replacement Therapy

Volumn 8, Issue 3, 2001, Pages 164-172

  Jörres, Achim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biocompatibility; Peritoneal dialysis; Peritoneal dialysis solutions; Peritoneal membrane

Indexed keywords

GLUCOSE;

ACIDOSIS; BIOCOMPATIBILITY; CELL FUNCTION; GLYCATION; HOMEOSTASIS; HOST RESISTANCE; HYPEROSMOLALITY; IMMUNOCOMPETENT CELL; MEMBRANE TRANSPORT; PERITONEAL DIALYSIS; PH; PRIORITY JOURNAL; REVIEW; ULTRAFILTRATION; UREMIA;

EID: 0034861796     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2001.26349     Document Type: Article

References (103)

1. Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions
2. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis
3. Structural and ultrastructural peritoneal membrane changes and permeability alterations during continuous ambulatory peritoneal dialysis
4. Peritoneal morphology on maintenance dialysis
5. Long-term effects of peritoneal dialysis on peritoneal morphology
6. Morphology of the peritoneum in CAPD
7. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients
8. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis
9. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis
10. Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha
11. Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1 beta and TNF alpha
12. Human peritoneal mesothelial cell prostaglandin synthesis: Induction of cyclooxygenase mRNA by peritoneal macrophage-derived cytokines
13. Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA
14. Human peritoneal fibroblast proliferation in 3-dimensional culture: Modulation by cytokines, growth factors and peritoneal dialysis effluent
15. Human peritoneal mesothelial cells synthesize IL-1 alpha and beta
16. Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis factor-alpha, interleukin-1, and medium conditioned by macrophages cocultured with Staphylococcus epidermidis
17. TNF-receptors on human peritoneal mesothelial cells: Regulation of receptor levels and shedding by IL-1 alpha and TNF alpha
18. The peritoneal fibroblast and the control of peritoneal inflammation
19. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GROalpha chemokine from mesothelial cells
20. Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity
21. Leukocyte migration across human peritoneal mesothelial cells is dependent on directed chemokine secretion and ICAM-1 expression
22. Peritoneal dialysis fluid inhibition of phagocyte function: Effects of osmolality and glucose concentration
23. Peritoneal dialysis fluid biocompatibility: Does it really matter?
24. Biocompatibility of peritoneal dialysis fluids
25. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro
26. Biocompatibility of peritoneal dialysis solutions
27. Biocompatibility studies on peritoneal cells
28. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis
29. Biocompatibility and buffers: Effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function
30. Peritoneal dialysis solution biocompatibility: Inhibitory mechanisms and recent studies with bicarbonate-buffered solutions
31. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD
32. Another reason to restrict the use of a hypertonic, glucose-based peritoneal dialysis fluid: Its impact on peritoneal macrophage function in vivo
33. Biocompatibility of dialysis solutions evaluated by histochemical techniques applied to mesothelial cell imprints
34. Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid
35. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions
36. Bicarbonate- versus lactate-based CAPD fluids: A biocompatibility study in rabbits
37. Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit
38. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: Influence on mesothelial cell and neutrophil function
39. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function
40. Bicarbonatebased dialysis solution preserves granulocyte functions
41. Improved cytosolic free calcium mobilization and superoxide production in bicarbonate-based peritoneal dialysis solution
42. A new lactate-based, plasticizer-free, neutral peritoneal dialysis fluid provided in a two-compartment system: Effect on peripheral leukocyte function
43. In vitro effects of bicarbonate- versus lactate-buffered continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function
44. In vitro biocompatibility of bicarbonatebased peritoneal dialysis solutions
45. Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum: Ultrastructural changes of reduplicated peritoneal basal membrane
46. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangiopathy
47. Biocompatibility of various osmotic solutes
48. Detrimental effects of peritoneal dialysis solutions upon in vivo and in situ exposed mesothelium
49. High glucose induces a hypertrophic, senescent mesothelial cell phenotype after long in vivo exposure
50. Effects of osmotic agents upon the in vivo exposed mesothelial monolayer
51. Chemistry of glucose and biochemical pathways of biological interest
52. Development of toxic degradation products during heat sterilization of glucose-containing fluids for peritoneal dialysis: Influence of time and temperature
53. Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose
54. Impact of terminal heat sterilization on the quality of peritoneal dialysis solutions
55. Heat sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations
56. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags
57. Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro
58. Glucose degradation and cytotoxicity in PD fluids
59. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes
60. Potentially irritant glucose metabolites in unused CAPD fluid
61. The effect of shelf life of peritoneal dialysis fluids on ultrafiltration in CAPD
62. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929
63. Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages
64. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro?
65. Heat sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes
66. Effect of glucose degradation products on human peritoneal mesothelial cell function
67. Heat-sterilized PD fluid blocks leukocyte adhesion and increases flow velocity in rat peritoneal venules
68. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats
69. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD
70. Accelerated formation of N epsilon-(carboxymethyl) lysine, an advanced glycation end product, by glyoxal and 3-deoxyglucosone in cultured rat sensory neurons
71. New biomarkers of Maillard reaction damage to proteins
72. In vitro formation of advanced glycation end products in peritoneal dialysis fluid
73. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation endproducts, during heat-sterilization of glucose-based peritoneal dialysis fluids
74. Elevated serum levels of 3-deoxyglucosone, a potent protein-crosslinking intermediate of the Maillard reaction, in uremic patients
75. Imidazolium crosslinks derived from reaction of lysine with glyoxal and methylglyoxal are increased in serum proteins of uremic patients: Evidence for increased oxidative stress in uremia
76. Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds
77. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration
78. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis
79. Strategies to reduce glucose exposure in peritoneal dialysis patients
80. Decreased in vitro formation of AGEs with extraneal solution compared to dextrose-containing peritoneal dialysis solutions
81. Glycation and advanced glycation end-product formation with icodextrin and dextrose
82. Cell function and viability in glucose polymer peritoneal dialysis fluids
83. In vitro-biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions
84. Maltose and isomaltose in uremic plasma following icodextrin administration
85. Direct determination of polyglucose metabolites in plasma using anion-exchange chromatography with pulsed amperometric detection
86. Allergic reactions to icodextrin in patients with renal failure
87. Icodextrin allergy in a peritoneal dialysis patient
88. Allergic reactions to the polymeric glucose-based peritoneal dialysis fluid icodextrin in patients with renal failure
89. Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid
90. Necrosis and apoptosis of polymorphonuclear cells exposed to peritoneal dialysis fluids in vitro
91. Biocompatibility of a peritoneal dialysis solution with amino acids: Histological evaluation in the rabbit
92. In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis
93. Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes
94. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids
95. First in vitro and in vivo experiences with stay-safe balance, a pH-neutral solution in a dual-chambered bag
96. Randomized long-term evaluation of bicarbonate-buffered CAPD solution
97. Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution
98. Bicarbonate-buffered CAPD solutions: From clinical trials to clinical practice
99. Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNF-alpha secretion
100. In vivo exposure to bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function
101. Longterm clinical effects of a peritoneal dialysis fluid with less glucose degradation products
102. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits
103. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain